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Abstract
Background: The complement system is vital for innate immunity and is implicated in the pathogenesis of
inflammatory diseases and the mechanism of host defense. Complement deficiencies occasionally cause life-
threatening diseases. In hemodialysis (HD) patients, profiles on complement functional activity and deficiency are
still obscure. The objectives of the present study were to measure the functional complement activities of the
classical pathway (CP), lectin pathway (LP) and alternative pathway (AP) using a novel method and consequently to
elucidate the rates of deficiencies among HD patients.
Methods: In the present study, 244 HD patients at one dialysis center and 204 healthy controls were enrolled.
Functional complement activities were measured simultaneously using the Wielisa®-kit. The combination of the
results of these three pathway activities allows us to speculate which candidate complement is deficient;
subsequently, the deficient complement was determined.
Results: All three functional complement activities were significantly higher in the HD patients than in the control
group (P < 0.01 for all cases). After identifying candidates in both groups with complement deficiencies using the
Wielisa®-kit, 16 sera (8.8%) with mannose-binding lectin (MBL) deficiency, 1 serum (0.4%) with C4 deficiency, 1
serum (0.4%) with C9 deficiency, and 1 serum (0.4%) with B deficiency were observed in the HD group, and 18
sera (8.8%) with MBL deficiency and 1 serum (0.5%) with B deficiency were observed in the control group. There
were no significant differences in the 5-year mortality rate between each complement-deficient group and the
complement-sufficient group among the HD patients.
Conclusion: This is the first report that profiles complement deficiencies by simultaneous measurement of
functional activities of the three complement pathways in HD patients. Hemodialysis patients frequently suffer from
infections or malignancies, but functional complement deficiencies do not confer additional risk of mortality.
Background
The complement system is part of the innate immune
system comprising at least 40 proteins that collaborate
in a complex fashion in the removal of microorganisms
and apoptotic cells, but also serves as an opsonin,
enhancing and directing adaptive immunity [1,2].
Complement deficiencies associated with several clin-
ical diseases involving impairment of the immune sys-
tem have been recognized. For example, various
reports suggest that complement deficiencies are highly
associated with an increased risk for infectious disease
[3,4]. Previous studies proposed that complement defi-
ciencies may be a risk factor for severe infections in
adults who had no evidence of bacterial/fungal infec-
tions in childhood and who have been undergoing che-
motherapy or transplant recipients [5,6]. Genetic
deficiencies of early components of the classical path-
way of complement activation are strongly associated
with the development of systemic lupus erythematosus
[7]. Recently, the antitumorigenic role of mannose-
binding lectin (MBL) was proposed since there was a
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ciated with MBL deficiency/insufficiency in ovarian
cancer patients than in the age-matched control group
[8].
Meanwhile, patients who receive hemodialysis (HD)
have various abnormalities of the immune system. HD
patients have increased susceptibility to infections and
have a high incidence of malignancy, which are possibly
linked with the immune response [9,10]. These abnorm-
alities of the immune system may be caused by the ure-
mic state or may occur as a direct consequence of HD
therapy. Identification of complement deficiencies in
HD patients would lead to a better understanding of the
clinical complications and the immune system of
patients in the uremic state; however, there is very little
information about the deficiencies.
There are three activation pathways of complement,
i.e., the classical pathway (CP), the alternative pathway
(AP), and the lectin pathway (LP). The CP is triggered
by binding of C1q to IgM or IgG antibodies which
bind to antigen, which in turn is translated into activa-
tion of the serine proteases C1r and C1 s. C1r cleaves
the complement components C4 and C2 to form the
C3 convertase C4b2a. The AP may start from sponta-
neous activation of C3 involving factor B (B), factor D
(D) and properdin (P). In the LP, MBL acts as the car-
bohydrate recognition molecule and activates comple-
ment association with the MBL-associated serine
protease 2 (MASP-2), C1r/C1s-like serine proteases,
which in turn catalyze C3 cleavage to C3b, which
binds to C4b2a to form C4b2a3b complex (C5 conver-
tase). Finally, the terminal complement complex is
formed through the terminal complement pathway
(C5, C6, C7, C8 and C9) activated by cleavage of C5
and causes bacteriolysis.
Recently, a commercially available kit (Wielisa®-kit,
Wieslab, Lund, Sweden) was developed to measure the
functional activities of the three complement pathways
in parallel for screening for complement deficiencies. In
brief, the wells are coated with specific activators of the
classical, alternative or lectin pathway. The sample
serum is diluted with different specific blockers to
ensure that only a specific pathway is activated. Subse-
quently, C5b-9 is detected with the relevant antibody to
the neoantigen expressed during the terminal comple-
ment complex formation. The amount of complement
activation is correlated with the color intensity and is
measured in terms of absorbance, and then the combi-
nation of the levels of the three activities can indicate
the deficient components.
In the present study, we determined the rates of com-
plement deficiencies among 244 HD patients using the
novel functional assay that can allow us to measure the
three complement activities simultaneously.
Methods
Hemodialysis patients and healthy controls
Serum samples were obtained from 244 HD patients
during a hemodialysis session at a single dialysis center
(Kasukabe Kisen Hospital, Saitama, Japan) in 2001 and
204 normal healthy controls who had no evidence of
renal disease. The hematocrit, hemoglobin, blood urea
nitrogen, serum creatinine, total protein, calcium and
phosphorus were determined in the serum samples from
the HD patients. In an effort to reduce the effect of
atherosclerosis by aging, group matching was performed
for age when comparing complement activities. The
characteristics of the HD patients and healthy controls
are shown in Additional file 1. We examined prospec-
tively the mortality rate in terms of complement defi-
ciency among the HD patients from 2001 to 2006. This
study was approved by the ethics committee of the
Kasukabe Kisen Hospital. All participants gave their
informed consent to take part in the study. The name of
the current protocol is “Clinical and Observational
Study in Hemodialysis Patients”,a n dt h i sr e s e a r c hw a s
performed in compliance with the Helsinki Declaration.
Blood samples
Blood samples from the HD patients were obtained
from the arterial side of the patient’sa r t e r i o v e n o u sf i s -
tula before anticoagulant injection at the beginning of
an HD session. All samples were immediately centri-
fuged at 3000 rpm at 4°C for 10 min, separated from
the cells and stored at -80°C until use.
Assay of three complement activation pathways
Measurement of the three functional complement activ-
ities was performed using a Wielisa®-kit (Wieslab, Lund,
Sweden). The enzyme-linked immunosorbent assays (ELI-
SAs) were developed according to the recommendation of
the manufacturer. The combination of the three assays for
complements can be helpful for detection of complement
deficiencies as shown in Additional file 2[11]. The negative
control is given the value of 0%, the positive control is
given the value of 100%, and subsequently, the values of
the sera were expressed as a percentage of the positive
control. Low functional complement activities of the CP
and AP were defined as serum levels below 5% according
to the recommendations of the manufacturer. In the LP
via MBL, low activity was also defined as below 5%
because there was no individual with MBL deficiency
among the individuals with the LP via MBL activation of
more than 5% in our study. These definitions were also
applied to the healthy control group.
Detection and measurement of complement components
S e r u mM B L ,M A S P - 2 ,B ,Da n dPc o n c e n t r a t i o n sw e r e
determined by ELISA. MBL, MASP-2 and D ELISA kits
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mark), Hycult Biotechnology b.v. (Uden, The Nether-
lands), and R&D Systems (Minneapolis, MN, US),
respectively. B and P ELISA kits were obtained from
USCN Life Science Inc. (Wuhan, China). Deficiency was
defined as less than 100 ng/mL, 170 ng/mL, 17 mg/dL, 30
ng/mL, and 0.2 mg/dL, for MBL, MASP-2, B, D and P,
respectively [12-15]. Serum C2, C5, C6, C7, C8 and C9
concentrations were quantified by nephelometry and
serum C3 and C4 concentrations were quantified by turbi-
dimetric immunoassay (SRL Inc., Tokyo, Japan); deficien-
cies of these complement proteins were defined as less
than their respective reference ranges according to SRL
Inc (reference ranges: C2:1.6-3.5 mg/dL, C3:86-160 mg/
dL, C4:17-45 mg/dL, C5:8-15 mg/dL, C6:2.5-4.5 mg/dL,
C7:2.4-4.6 mg/dL, C8:5.5-8.9 mg/dL, C9:2.7-7.3 mg/dL).
Statistical analysis
All statistical analyses were performed using StatView
for Windows, version 5.0 (SAS Institute Inc., Cary, NC).
The functional activities of the three complement path-
ways were measured in sera obtained from the HD
patients and healthy controls. The functional activities
of CP as well as AP formed normal distributions, and
the functional activity of LP formed a roughly bimodal
distribution among both the HD patients and healthy
controls. The data were expressed as mean ± SD. The
Mann−Whitney U-test was used to test the significance
of the difference in the three complement pathway
activities between the HD patients and healthy controls.
Chi-square test was used to test the significance of the
difference in frequencies between two groups. A P-value
of < 0.01 was considered statistically significant.
Results
Functional activities of three complement pathways
The mean CP, LP and AP activities in the HD group
were 111.7 ± 30.6%, 117.4 ± 74.9% and 109.3 ± 23.1%,
respectively, and those in the control group were 85.6 ±
18.9%, 68.4 ± 50.6% and 68.7 ± 25.6%, respectively. The
levels of all three functional complement activities were
significantly higher in the HD patients than in the con-
trol group (P < 0.01 for all cases; Figure 1a). After group
matching for age, the levels of all three functional com-
plement activities were still higher in the HD patients
than in the control group (CP, 125.8 ± 33.2% vs. 90.1 ±
19.8%; LP, 115.5 ± 82.0% vs. 67.1 ± 51.1%; AP, 109.9 ±
22.9% vs. 81.0 ± 19.0%; P < 0.01 for all cases; Figure 1b).
Moreover, upon comparison of the levels of the three
functional complement activities between HD patients
who used modified cellulose membrane (n = 35) and
HD patients who used polysulfone membrane (n = 29)
in the age-matched group, there were no significant dif-
ferences (data not shown).
Complement deficiencies
In the HD group, 27 (11.1%) of the 244 samples had low
functional activity of one or more complement path-
ways: 22 (9.0%) had a combination of low LP and nor-
mal CP and AP activities, and 3 (1.2%) had a
combination of low CP and LP and normal AP activities
(Additional file 3). Moreover, 1 (0.4%) had a combina-
tion of low functional activity of all three pathways, and
1 (0.4%) had a combination of low AP and normal CP
and LP activities. In the control group, 32 (15.7%) of the
204 samples had low functional activity of one or more
complement pathways: 31 (15.2%) had a combination of
low LP and normal CP and AP activities, and 1 (0.5%)
had a combination of low AP and normal CP and LP
activities.
To determine which complement was deficient among
the HD patients and healthy controls, further experi-
ments were performed according to the combination of
the low complement pathway activities (Additional file
2). Additional file 4 Additional file 5 and Additional file
6 show the concentrations of the individual complement
proteins in each group. In the HD group, there were 16
patients (6.6%) with MBL deficiency but with sufficient
MASP-2 among the 22 patients who presented with low
LP and normal CP and AP activities, 1 patient (0.4%)
with C4 deficiency but with sufficient C2 among the 3
patients who presented with low CP and LP and normal
AP activities, 1 patient (0.4%) with C9 deficiency but
with sufficient C5, C6, C7 and C8, who was the only
patient presenting low activities of all three pathways, 1
patient (0.4%) with B deficiency but with sufficient D
and P, who was the only patient presenting with low AP
and normal CP and LP activities. In the control group,
18 individuals (8.8%) with MBL deficiency and 1 indivi-
dual with B deficiency (0.5%) were observed. There were
Figure 1 Comparison of the activities of the classical (CP),
lectin (LP) and alternative pathways (AP) in hemodialysis (HD)
patients and healthy controls. White column indicates HD
patients, and black column indicates healthy controls. (a) The HD
patients enrolled in the present study had significantly higher
activity levels of all three complement pathways than the 204
healthy controls. (b) After group matching for age, 64 HD patients
also had significantly higher activity levels of all three complement
pathways compared with the 56 healthy controls. *P < 0.01; data
are shown as the mean ± SD.
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deficiencies in the present study between the HD group
and control group (Additional file 7).
Outcomes of the hemodialysis patients
The five-year mortality rate from all causes among the
HD patients with MBL, C4 or C9 deficiency from 2001
to 2006 was investigated. During this period, 3 deaths
were observed among the 16 patients with MBL defi-
ciency, of which 1 was caused by heart failure, 1 was
caused by hepatocellular carcinoma and 1 was caused
by intracerebral hemorrhage. No deaths were observed
among the individuals with C4, C9 and B deficiency,
respectively. Although the five-year mortality rate of
each complement-deficient group was lower than that of
the complement-sufficient group, there were no signifi-
cant differences between each complement-deficient
group and the complement-sufficient group (Additional
file 8).
Discussion
The complement system is increasingly recognized to
have both a protective role and a pathogenic role in the
maintenance of renal physiology [16-19]. In this study,
we focused on the intricate functions of the immune
system including complements especially in patients
with end-stage renal disease. Hemolytic assays (e.g.,
CH50 or AH50) are widely performed to assess comple-
ment activity and detect complement deficiency, but
there are some problems in terms of cost and effective-
ness. A novel ELISA kit, the Wielisa®-kit, was recently
developed to assess the three complement pathways
independently and in parallel. Microtiter plates were
coated with each ligand that causes the activation of
each complement pathway, and the readout is incor-
poration of C9 in the terminal complement complex,
C5b-9. Subsequently, certain combinations of the three
results for functional complement activity can allow us
to speculate possible deficient components more easily
than the hemolytic assays.
The first important finding in the current study was
that the rates of low functional complement activity and
complement deficiency did not significantly differ
between the HD patients and healthy controls, and the
mortality rate did not significantly differ between the
complement-deficient group and complement-sufficient
group among the HD patients. Complement deficiency
is a possible risk factor for infections or malignancy as
described above. However, complement deficiencies
were not associated with mortality from all causes
among the HD patients in our study. These findings
might be explained by the beneficial aspect of HD that
the patients need to visit a medical facility three times a
week and would undergo examinations immediately if
they feel sick. Unfortunately, data on hospitalizations in
the complement-sufficient group were not available and
for this reason, we cannot study the relationship
between complement deficiencies and hospitalization for
infection. As far as the available data, the total number
of admissions for all causes among the HD patients with
MBL deficiency were 30, and 7 of them were hospita-
lized due to infection: 3 had acute enteritis, 1 had acute
bronchitis, 1 had pneumonia, 1 had tuberculosis and 1
was unknown. The total number of admissions for all
causes in the patient with C4 deficiency was 8, and 2 of
them were for infections: 1 had acute bronchitis and 1
had influenza. The patient with C9 deficiency and the
patient with B deficiency were not hospitalized during
the study period. With regard to the detection of the B
deficiency, the Ouchterlony method was also performed
before measurement of B concentrations by ELISA.
Although B levels in sera of the patient and control with
low AP activity were very low based on ELISA, the pre-
cipitate line could be seen by observing between the
anti-B polyclonal antibody and the samples from the
results of the Ouchterlony method. This discrepancy
may be explained by the fact that ELISA antibodies
recognized different epitopes from those recognized by
the Ouchterlony method antibody. In the present study,
we weighted the ELISA results heavily and defined both
the patient and the control as B deficient because these
results, including results from the Wielisa®-kit indicated
the possibility that the two cases had B structural
abnormalities or genetic disorders.
The second finding in the current study was that indi-
viduals on HD had significantly higher levels of func-
tional complement activity of all three pathways than
healthy controls. In addition, we performed group
matching to reduce the effect of aging because recent
evidence pointed to an association between excessive
complement activity and many diseases relevant to
aging such as atherosclerosis or lipid metabolism
[20,21], and the activity levels of all three pathways were
also significantly higher in the HD patients than in the
controls. These results suggest that the concentration of
C3 and the late complement components (C5, C6, C7,
C8 and C9) may be increased in HD patients with the
high complement activities. These possibilities are inter-
esting because the sera of HD patients in present study
were obtained before HD, not after HD. Many research
groups report that dialysis membranes cause varying
degrees of complement activation during HD [22], and
the concentrations of C3 and late complement compo-
nents in sera obtained before HD have been studied in a
few reports [23]. Measurement of the concentration of
C3 and the late complement components before and
after HD should be conducted in a large number of HD
patients. One potential explanation for the uncontrolled
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proteins in the serum may be reduced in the patients.
To the best of our knowledge, there are no reports on
the association between HD and various serum regula-
tory proteins. A few reports investigated only erythro-
cyte complement receptor type 1 (E-CR1) among HD
patients as follows: recombinant human erythropoietin
improved anemia and increased the level of E-CR1 [24],
and a low level of E-CR1 was associated with poor prog-
nosis in HD patients [25]. Meanwhile, deficiency of
complement regulatory proteins often occurs along with
decreased levels of other complement proteins. For
example, C1 esterase inhibitor (C1-INH) deficiency,
which is one of the important risk factors of hereditary
angioedema (HAE), is associated with an increased clea-
vage of C4 by C1, which results in low C4 levels during
the attack. Three HD patients with low CP and LP and
normal AP activities in our study may also have had low
C4 level due to C1-INH deficiency, but we could not
measure the complement regulatory protein because
we did not have enough serum. Examination of
these patients including family history did not reveal
symptoms that suggested HAE, such as recurrent and
transient swelling of face, extremities and airway. Com-
plement regulatory proteins in serum should be studied
in the near future to clarify complement-mediated
inflammatory manifestations.
Conclusions
The present study is the first to demonstrate the func-
tional activities of three complement pathways in paral-
lel and the rates of several complement deficiencies
among HD patients. Although complement deficiency
was suggested to be partially responsible for infection or
malignancy, the results of our study suggest that com-
plement deficiencies do not play a role in mortality in
HD patients. Nevertheless, these results also suggest
that complement deficiencies exist among HD patients
as well as healthy individuals, and HD patients with
complement deficiency shall be observed more carefully.
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